Clarity Pharmaceuticals (ASX:CU6)
ASX announcement history & article coverage
Transparent by design.
Announcments by Clarity Pharmaceuticals (ASX:CU6) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Ceasing to be a substantial holder
Ceasing to be a substantial holder
Cleansing Notice
Application for quotation of securities - CU6
Becoming a substantial holder
Data on SAR-bisPSMA to be presented at EANM
Clarity Pharmaceuticals to present promising prostate cancer imaging and therapy data at EANM 2026
Clarity celebrates 100-employee milestone
Ceasing to be a substantial holder
Ceasing to be a substantial holder
Change in substantial holding
Becoming a substantial holder
Notification regarding unquoted securities - CU6
Cleansing Notice
Application for quotation of securities - CU6
Clarity receives $9.8 million R&D tax incentive refund
Clarity Pharmaceuticals secures $9.8 million R&D tax refund to advance cancer treatment development
Quarterly Activities/Appendix 4C Cash Flow Report
Clarity Pharmaceuticals reports positive Phase II trial results, strong Phase III progress, manufacturing deals, and $197.8M cash
Change of Director's Interest Notice - Parker
Clarity signs a Commercial Manufacturing Agreement
Clarity signs manufacturing deal with Nucleus RadioPharma for prostate cancer imaging agent
